Adial Pharmaceuticals (ADIL) late Friday said Alumni Capital plans to sell up to 5 million shares of its stock from time to time, including 68,807 shares it issued through a commitment agreement.
The upcoming stock sale could include shares acquired by Alumni Capital through a $5 million purchase agreement disclosed late last week.
The preliminary prospectus filed Friday does not require Alumni Capital to sell a particular number of shares or establish a deadline or set a price for any future stock sale, Adail Pharmaceuticals said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments